Literature DB >> 28882945

Melatonin Synergizes the Chemotherapeutic Effect of Cisplatin in Ovarian Cancer Cells Independently of MT1 Melatonin Receptors.

Agata Zemła1, Irmina Grzegorek1, Piotr Dzięgiel2,3, Karolina Jabłońska1.   

Abstract

BACKGROUND/AIM: Melatonin (MLT), through the interaction with membrane melatonin receptors MT1, can improve the effectiveness of cytostatic agents, including cisplatin (CP). The aim of this study was to examine the synergistic effect of MLT and CP in three cell lines: IOSE 364, SK-OV-3 and OVCAR-3, as well as to assess the role of MT1 receptors in this mechanism.
MATERIALS AND METHODS: Using the SRB assay we investigated the effect of different concentrations of CP and MLT on cell viability. Tests, using luzindole - MT1 inhibitor, allowed us to assess the potential involvement of MT1 in the mechanism of MLT action.
RESULTS: MLT at certain concentrations demonstrated a synergistic effect in combination with CP. The addition of luzindole did not affect the action of MLT in combination with CP.
CONCLUSION: In summary, the synergistic effect of MLT with CP seems to be independent of membrane MT1 receptors. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  MT1 melatonin receptor; Melatonin; chemotherapy; cisplatin; ovarian cancer

Mesh:

Substances:

Year:  2017        PMID: 28882945      PMCID: PMC5656852          DOI: 10.21873/invivo.11133

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  61 in total

Review 1.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Authors:  Jiabei Liu; Shannon J Clough; Anthony J Hutchinson; Ekue B Adamah-Biassi; Marina Popovska-Gorevski; Margarita L Dubocovich
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

Review 2.  Update on melatonin receptors: IUPHAR Review 20.

Authors:  Ralf Jockers; Philippe Delagrange; Margarita L Dubocovich; Regina P Markus; Nicolas Renault; Gianluca Tosini; Erika Cecon; Darius P Zlotos
Journal:  Br J Pharmacol       Date:  2016-08-08       Impact factor: 8.739

3.  Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1α.

Authors:  Wenjing Su; Lei Huang; Qilin Ao; Qinghua Zhang; Xun Tian; Yong Fang; Yunping Lu
Journal:  Cancer Lett       Date:  2011-03-21       Impact factor: 8.679

4.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

Review 5.  Melatonin: therapeutic and clinical utilization.

Authors:  A Altun; B Ugur-Altun
Journal:  Int J Clin Pract       Date:  2007-02-13       Impact factor: 2.503

6.  Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma.

Authors:  Erina Nakamura; Ken-ichi Kozaki; Hitoshi Tsuda; Emina Suzuki; Atiphan Pimkhaokham; Gou Yamamoto; Tarou Irie; Tetsuhiko Tachikawa; Teruo Amagasa; Johji Inazawa; Issei Imoto
Journal:  Cancer Sci       Date:  2008-04-29       Impact factor: 6.716

Review 7.  [MT1 melatonin receptors and their role in the oncostatic action of melatonin].

Authors:  Karolina Danielczyk; Piotr Dziegiel
Journal:  Postepy Hig Med Dosw (Online)       Date:  2009-09-15       Impact factor: 0.270

8.  Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro.

Authors:  Mercedes M Leon-Blanco; Juan M Guerrero; Russel J Reiter; Juan R Calvo; David Pozo
Journal:  J Pineal Res       Date:  2003-10       Impact factor: 13.007

9.  Therapeutic applications of melatonin.

Authors:  Ifigenia Kostoglou-Athanassiou
Journal:  Ther Adv Endocrinol Metab       Date:  2013-02       Impact factor: 3.565

10.  Expression of the MT1 melatonin receptor in ovarian cancer cells.

Authors:  Karolina Jablonska; Bartosz Pula; Agata Zemla; Christopher Kobierzycki; Witold Kedzia; Ewa Nowak-Markwitz; Marek Spaczynski; Maciej Zabel; Marzenna Podhorska-Okolow; Piotr Dziegiel
Journal:  Int J Mol Sci       Date:  2014-12-12       Impact factor: 5.923

View more
  4 in total

Review 1.  Melatonin and its mechanism of action in the female reproductive system and related malignancies.

Authors:  Maryam Ezzati; Kobra Velaei; Raziyeh Kheirjou
Journal:  Mol Cell Biochem       Date:  2021-04-17       Impact factor: 3.396

Review 2.  Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.

Authors:  Wamidh H Talib; Ahmad Riyad Alsayed; Alaa Abuawad; Safa Daoud; Asma Ismail Mahmod
Journal:  Molecules       Date:  2021-04-25       Impact factor: 4.411

3.  Melatonin Reverses the Warburg-Type Metabolism and Reduces Mitochondrial Membrane Potential of Ovarian Cancer Cells Independent of MT1 Receptor Activation.

Authors:  Maira Smaniotto Cucielo; Roberta Carvalho Cesário; Henrique Spaulonci Silveira; Letícia Barbosa Gaiotte; Sérgio Alexandre Alcantara Dos Santos; Debora Aparecida Pires de Campos Zuccari; Fábio Rodrigues Ferreira Seiva; Russel J Reiter; Luiz Gustavo de Almeida Chuffa
Journal:  Molecules       Date:  2022-07-07       Impact factor: 4.927

Review 4.  Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers.

Authors:  Javier Menéndez-Menéndez; Carlos Martínez-Campa
Journal:  Int J Endocrinol       Date:  2018-10-02       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.